Partnered products
4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.
Sold to Immunic Inc.
IMU-838 is an orally available, next-generation, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) which plays a key role in the metabolism of activated T and B cells while leaving other immune cells largely unaffected.